Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmatrix (PULM) Cash & Equivalents (2016 - 2025)

Pulmatrix's Cash & Equivalents history spans 13 years, with the latest figure at $4.1 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 57.06% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $4.1 million, down 57.06%, while the annual FY2025 figure was $4.1 million, 57.06% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $4.1 million at Pulmatrix, down from $4.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $63.4 million in Q1 2021 and bottomed at $4.1 million in Q4 2025.
  • The 5-year median for Cash & Equivalents is $23.6 million (2023), against an average of $28.1 million.
  • The largest annual shift saw Cash & Equivalents surged 160.0% in 2021 before it tumbled 57.06% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $53.8 million in 2021, then plummeted by 33.83% to $35.6 million in 2022, then crashed by 46.19% to $19.2 million in 2023, then crashed by 50.34% to $9.5 million in 2024, then crashed by 57.06% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for PULM's Cash & Equivalents are $4.1 million (Q4 2025), $4.8 million (Q3 2025), and $5.8 million (Q2 2025).